Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Clinical Update

Early treatment of acute hepatitis C infection may lead to cure

John Hoey
CMAJ November 27, 2001 165 (11) 1527;
John Hoey
Eric Wooltorton, CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001 (early release). Available: content.nejm.org/cgi/reprint /NEJMoa 011232v1 .pdf (accessed 2001 Oct 26).

Background: Infection with hepatitis C virus (HCV) is common, affecting about 1% of the Canadian population1 and an estimated 170 million people worldwide.2 Infection occurs through the transmission of body fluids, usually because of injection drug use, needle-stick injuries, other medical misadventures or, rarely, sexual contact. About 70% of those infected develop chronic infection and 20% of them will develop cirrhosis.2 Hepatitis C is a serious infection and is the single most common reason for liver transplantation.1

Although peginterferon alfa-2b (an interferon with attached polyethylene glycol moiety and extended half-life) in combination with ribavirin appears to be an effective treatment for chronic HCV infection, only about 50% of patients appear to benefit.3 These researchers wondered whether therapy would be more effective if treatment was begun in the early course of illness as opposed to later when the infection became chronic.

Question: Does administration of interferon alfa-2b in the acute phase of HCV infection prevent progression to chronic infection?

Design: In a study conducted throughout Germany, investigators identified 44 patients who tested positive for HCV RNA (by polymerase-chain-reaction assay), had elevated serum alanine aminotransferase levels and had been diagnosed with acute HCV infection (i.e., if 1 or more of the following criteria was met: known or suspected exposure to HCV within the preceding 4 months, documented seroconversion with a known previous negative HCV test, or a serum alanine aminotransferase level of more than 350 U/L, with a documented normal level during the year before infection). There were numerous exclusion criteria, including other causes of hepatitis, HIV infection or contraindications to interferon therapy, such as a history of severe depression, neutropenia or thrombocytopenia, decompensated liver disease, seizures, decompensated thyroid disease and other autoimmune diseases. Study subjects were treated subcutaneously with 5 million U of interferon alfa-2b (a recombinant version of human interferon alpha-2b) daily for 4 weeks, and then 3 times per week for another 20 weeks. Biochemical and hematologic testing was performed regularly during treatment, at the completion of treatment and 24 weeks after treatment ceased. There was no control group.

Results: Twenty-five women and 19 men with an average age of 36 were identified and treated. Sources of HCV infection were: needle-stick injuries (14), other medical procedures (7), sexual contact (10), intravenous drug use (9) and uncertain (4). The average time from presumed infection to the signs or symptoms of the disease was 54 days (range, 15–105 d), and the average time from infection until the start of therapy was 89 days (range 30–112 d).

All 44 patients experienced rapid decreases in alanine aminotransferase levels (normalizing in 80% of patients after 24 weeks of therapy, and in the rest by the end of follow-up), and serum levels of HCV RNA became undetectable for all patients (mean time before levels were undetectable, 3.2 wk). One patient stopped treatment after 12 weeks because of hair loss and influenza-like symptoms and was lost to follow-up. After 24 weeks of follow-up, the remaining 43 patients still had undetectable levels of HCV RNA.

All patients experienced known side effects of interferon alfa-2b therapy, including thrombocytopenia (with platelet count dropping at week 4 to an average of 161 × 109/L) and leukopenia (with average count at week 4 of 3.9 × 109/L), which both reversed after therapy was completed. Except for the single patient, side effects were not severe and no dosage adjustments were needed.

Commentary: This is a carefully conducted study. Although there is no control group, the 100% success rate of treatment might now preclude, ethically, a randomized placebo-controlled clinical trial. Spontaneous remission of HCV infection appears to occur in about 30% of patients, so some of the benefit or cure attributed to interferon alfa-2b in this study would have occurred without therapy. The authors knew this and looked at their data for predictors of early response to treatment but were unable to identify any.

Practice implications: This study strongly suggests a beneficial effect from intensive therapy with interferon alfa-2b administered early in the course of HCV infection. Side effects appear minimal. Follow-up was not reported beyond the end of active therapy, but patients appeared to have levels of HCV RNA that are undetectable by current methods; presumably, they had been cured. These cure rates are substantially better than those reported for the current treatment of chronic HCV infection, which eliminates the virus in about 50% of patients.2

Anyone with recent-onset acute HCV infection should be informed of the potential value of therapy with interferon alfa-2b. The authors point out that more studies are needed to determine if less intensive therapy will be equally effective, and longer follow-up of treated patients is needed to ascertain cure rates.

References

  1. 1.↵
    Gutfreund KS, Bain VG. Chronic viral hepatitis C: management update. CMAJ 2000;162(6): 827-33.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Lauer GM, Walker BD. N Engl J Med 2001; 345(1):41-52
    OpenUrlCrossRefPubMed
  3. 3.↵
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindolar R, et al. Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

CMAJ
Vol. 165, Issue 11
27 Nov 2001
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Early treatment of acute hepatitis C infection may lead to cure
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Early treatment of acute hepatitis C infection may lead to cure
John Hoey
CMAJ Nov 2001, 165 (11) 1527;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Early treatment of acute hepatitis C infection may lead to cure
John Hoey
CMAJ Nov 2001, 165 (11) 1527;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Angiotensin-II–receptor blockers and nephropathy in patients with type 2 diabetes
  • Colorectal cancer screening: you can't be positive about a negative result
Show more Clinical Update

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire